Alzheimer's disease (AD) is a neurodegenerative disorder that impairs mental ability
development and interrupts neurocognitive function. This neuropathological condition is …

Neurological disorders such as Alzheimer's disease, stroke, and brain cancers are difficult to
treat with current drugs as their delivery efficacy to the brain is severely hampered by the …

Therapies directed toward the central nervous system remain difficult to translate into
improved clinical outcomes. This is largely due to the blood–brain barrier (BBB), arguably …

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease which is mainly
characterized by progressive impairment in cognition, emotion, language and memory in …

Peptide–and protein–nanoparticle conjugates have emerged as powerful tools for
biomedical applications, enabling the treatment, diagnosis, and prevention of disease. In …

Obtaining efficient drug delivery to the brain remains the biggest challenge for the
development of therapeutics to treat diseases of the central nervous system. The main …

Recent advances in technology are expected to increase our current understanding of
neuroscience. Nanotechnology and nanomaterials can alter and control neural functionality …

Central nervous system diseases are a heavy burden on society and health care systems.
Hence, the delivery of drugs to the brain has gained more and more interest. The brain is …

Gold nanoparticles (AuNPs) have been extensively used as nanomaterials for theranostic
applications due to their multifunctional characteristics in therapeutics, imaging, and surface …

Brain delivery is one of the major challenges in drug development because of the high
number of patients suffering from neural diseases and the low efficiency of the treatments …